Trial · NCT06855433
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Interleukin 18 (IL-18) | Baseline and Week 24 | Serum IL-18 |
| Secondary | Serum IL-1b | Baseline and Week 24 | Serum IL-1b |
| Secondary | Serum IL-17A | Baseline and Week 24 | Serum IL-17A |
| Secondary | High-sensitivity C-reactive protein (hsCRP) | Baseline and Week 24 | High-sensitivity C-reactive protein in blood |
| Secondary | IL-1b gene signature expression in PBMCs | Baseline and Week 24 | Expression of a panel of genes involved in IL-1b production or signaling, as percentage of total gene expression per cell |
| Secondary | Immune cell population frequencies | Baseline and Week 24 | Immune cell clusters among PBMCs |
| Secondary | Pain visual analog scale (pain VAS) | Baseline, Week 12, Week 24 | Severity of pain from CPPD disease/pseudogout, both at rest and with activity, in the past 7 days (range 0-100mm, with 0 indicating no pain) |
| Secondary | Brief Pain Inventory (Short Form) | Baseline, Week 12, Week 24 | Brief Pain Inventory includes two sub-scores: Pain Severity Score (range 0-10, with 0 indicating no pain in the past 24 hours) and Pain Interference Score (range 0-10, with 0 indicating no interference in the past 24 hours) |
| Secondary | Pain in the past week (PEG [pain intensity [P], interference with enjoyment of life [E], and interference with general activity [G]) | Baseline, Week 12, Week 24 | 3 question instrument, range 0-10, with 0 indicating no pain and no interference in the past week |
| Secondary | Patient Reported Outcome Measurement Information System (PROMIS)-Physical Function | Baseline, Week 12, Week 24 | PROMIS-Physical Function Short Form 10a (T-score range 0-100, with higher scores indicating better physical function) |
| Secondary | Patient Global Assessment of Response to Treatment | Week 12, Week 24 | 5 point Likert scale |
| Secondary | Patient Global Assessment | Baseline, Week 12, Week 24 | Patient Global Assessment of CPPD Disease Activity (range: 0-10) |
| Secondary | Physician Global Assessment | Baseline, Week 12, Week 24 | Physician's Global Assessment of CPPD Disease Activity (range: 0-10) |
| Secondary | Flare count | Week 12, Week 24 | Number of acute calcium pyrophosphate crystal arthritis flares |
| Secondary | Adverse events | Week 12, Week 24 | Number of expected adverse events and unexpected adverse events |
| Secondary | Tender Joint Count | Baseline, Week 12, Week 24 | Tender Joint Count |
| Secondary | Swollen Joint Count | Baseline, Week 12, Week 24 | Swollen Joint Count |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06855433/registered